[go: up one dir, main page]

PE20150203A1 - Formulas de testosterona proliposomal - Google Patents

Formulas de testosterona proliposomal

Info

Publication number
PE20150203A1
PE20150203A1 PE2014002002A PE2014002002A PE20150203A1 PE 20150203 A1 PE20150203 A1 PE 20150203A1 PE 2014002002 A PE2014002002 A PE 2014002002A PE 2014002002 A PE2014002002 A PE 2014002002A PE 20150203 A1 PE20150203 A1 PE 20150203A1
Authority
PE
Peru
Prior art keywords
formulas
testosterone
proliposomal
refers
proliposomal testosterone
Prior art date
Application number
PE2014002002A
Other languages
English (en)
Inventor
Guru V Betageri
Ramachandran Trirucote
Veeran Gowda Kadajji
Original Assignee
Univ Western Health Sciences
Tesorx Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49551459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150203(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Western Health Sciences, Tesorx Pharma Llc filed Critical Univ Western Health Sciences
Publication of PE20150203A1 publication Critical patent/PE20150203A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE INCLUYE UNA DISPERSION DE POLVOS PROLIPOSOMALES QUE CONTIENE: A) TESTOSTERONA EN UNA CANTIDAD DE 100 A 260MG; B) COLESTEROL; Y C) UN FOSFOLIPIDO TAL COMO DIESTEAROILFOSFATIDILCOLINA. LA FORMA FARMACEUTICA DE DICHA COMPOSICION ES TABLETA O CAPSULA QUE TIENE UN REVESTIMIENTO ENTERICO. TAMBIEN SE REFIERE A METODOS DE TRATAMIENTO PARA LA TERAPIA DE REEMPLAZO DE TESTOSTERONA
PE2014002002A 2012-05-09 2013-05-09 Formulas de testosterona proliposomal PE20150203A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261644996P 2012-05-09 2012-05-09

Publications (1)

Publication Number Publication Date
PE20150203A1 true PE20150203A1 (es) 2015-02-01

Family

ID=49551459

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014002002A PE20150203A1 (es) 2012-05-09 2013-05-09 Formulas de testosterona proliposomal

Country Status (32)

Country Link
US (5) US8957053B2 (es)
EP (1) EP2846781B1 (es)
JP (3) JP6055088B2 (es)
KR (1) KR20150032939A (es)
CN (2) CN104780914B (es)
AP (1) AP2014008099A0 (es)
AR (1) AR091006A1 (es)
AU (2) AU2013259509B2 (es)
BR (1) BR112014027942A2 (es)
CA (1) CA2872779A1 (es)
CL (1) CL2014003034A1 (es)
CO (1) CO7240373A2 (es)
CR (1) CR20140561A (es)
DO (1) DOP2015000026A (es)
EA (2) EA201791738A1 (es)
EC (1) ECSP14030572A (es)
GE (1) GEP201706754B (es)
HK (2) HK1210409A1 (es)
IL (1) IL235464B (es)
IN (1) IN2014DN10383A (es)
MA (1) MA37610B1 (es)
MX (1) MX367123B (es)
MY (1) MY175305A (es)
NZ (2) NZ721900A (es)
PE (1) PE20150203A1 (es)
PH (1) PH12014502498A1 (es)
SG (2) SG10201702240TA (es)
TN (1) TN2014000467A1 (es)
TW (2) TWI664982B (es)
UA (1) UA115058C2 (es)
WO (1) WO2013170012A2 (es)
ZA (2) ZA201408996B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10213440B2 (en) 2014-08-20 2019-02-26 Professional Compounding Centers Of America (Pcca) Oral transmucosal pharmaceutical compositions including testosterone and an aromatase inhibitor
KR101682821B1 (ko) 2015-07-21 2016-12-06 서울대학교산학협력단 프로리포솜 제조방법
DK3400072T3 (da) * 2016-01-07 2021-03-22 Tesorx Pharma Llc Formuleringer til behandling af blærecancer
EP3399965A4 (en) * 2016-01-08 2019-08-21 Western University Of Health Sciences PROLIPOSOMAL TESTOSTERONE ANDECANOATE FORMULATIONS
KR102574139B1 (ko) 2016-07-07 2023-09-05 삼성전자주식회사 무선 충전 모드를 변경하는 장치 및 방법
EP3538074B1 (en) 2016-11-11 2023-07-26 Western University Of Health Sciences Methods of treating upper tract urothelial carcinomas
MX2020005012A (es) 2017-11-17 2020-08-27 Evonik Operations Gmbh Procedimiento de preparacion de una capsula de envoltura dura revestida.
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
US20200101085A1 (en) * 2018-09-28 2020-04-02 Joel Studin Transpore delivery of drugs and uses thereof
CN120420296A (zh) * 2019-05-15 2025-08-05 赢创运营有限公司 用胶囊填充机制备具有基于(甲基)丙烯酸酯共聚物的包衣的填充硬壳胶囊的方法
WO2020229192A1 (en) * 2019-05-15 2020-11-19 Evonik Operations Gmbh Process for preparing filled hard-shell capsules with cellulose or starch-based coatings with a capsule-filling machine
WO2021030260A1 (en) * 2019-08-09 2021-02-18 Tesorx Pharma, Llc Proliposomal testosterone undecanoate formulations
CN110747271B (zh) * 2019-12-02 2023-07-18 延边大学 关于pci术后血管损伤-再狭窄程度的标记物
JP6945874B2 (ja) * 2019-12-24 2021-10-06 一般財団法人バイオダイナミックス研究所 経口投与用医薬組成物
CN111840240A (zh) * 2020-05-29 2020-10-30 仁和堂药业有限公司 一种非那雄胺制剂及其应用
CN112121003B (zh) * 2020-09-29 2022-02-01 江苏集萃新型药物制剂技术研究所有限公司 缓释制剂载药材料及其组合物、缓释制剂及其制备方法
EP4340838A4 (en) * 2021-05-19 2025-04-16 Alberto Paz ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT
CN114668719B (zh) * 2022-02-21 2023-06-16 广东食品药品职业学院 双氢睾酮混悬剂与双氢睾酮冻干粉及其制备方法
TW202417004A (zh) * 2022-09-16 2024-05-01 大陸商長春金賽藥業有限責任公司 類固醇激素磷脂組合物及其製備方法
CN117018211B (zh) * 2023-07-31 2025-09-09 沈阳药科大学 一种睾酮-胆固醇前药及制备方法和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744989A (en) 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US5002936A (en) 1985-04-12 1991-03-26 Seymour Lieberman Lipophilic complexes of pharmacologically active inorganic mineral acid esters of organic compounds
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
EP0361928B1 (en) 1988-09-29 1994-04-27 Shiseido Company Limited Emulsified composition
IE904098A1 (en) 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US20040175417A1 (en) 1990-10-19 2004-09-09 Gilead Sciences, Inc. Amphotericin B liposome preparation
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JP3017906B2 (ja) 1993-10-08 2000-03-13 信越化学工業株式会社 腸溶性コーティング剤分散液
US6214375B1 (en) 1996-07-16 2001-04-10 Generex Pharmaceuticals, Inc. Phospholipid formulations
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6761901B1 (en) * 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
WO2002051426A2 (en) 2000-12-22 2002-07-04 A Glenn Braswell COMPOSITIONS AND METHODS FOR TREATING SEXUAL DYSFUNCTIONS, IMPROVING SEXUAL ACTIVITY AND INCREASING TESTOSTERONE LEVELS, AND IMPROVING MUSCLE STRENGTH AND MASS
US6534080B2 (en) 2001-02-12 2003-03-18 Super Gen, Inc. Method for administering camptothecins via injection of pharmaceutical composition comprising coated particles of a camptothecin
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
US8658202B2 (en) 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
US20040115226A1 (en) 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
WO2004100927A2 (de) 2003-05-12 2004-11-25 Novosom Ag Injizierbare depots aus liposomalen aggregaten zum wirkstoffdelivery
ATE509618T1 (de) 2003-11-05 2011-06-15 Elan Pharma Int Ltd Nanoteilchenförmige zusammensetzungen mit einem peptid als oberflächenstabilisator
US20060051406A1 (en) 2004-07-23 2006-03-09 Manjeet Parmar Formulation of insoluble small molecule therapeutics in lipid-based carriers
WO2006062506A1 (en) * 2004-12-03 2006-06-15 Enzrel, Inc. Chitosan-coated liposome drug delivery of antioxidant or anti-inflammatory compounds
JP2009518443A (ja) 2005-12-06 2009-05-07 リゲル ファーマシューティカルズ インコーポレーティッド 脂質を主材料とする担体に内封された、不溶性小分子治療剤の製剤
US20070154403A1 (en) 2006-01-05 2007-07-05 Thomas Skold Oral, Pulmonary and Transmucosal Delivery Composition
CA2660310C (en) 2006-03-30 2015-04-21 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
WO2008114274A1 (en) * 2007-03-19 2008-09-25 Fresenius Kabi Onclology Ltd. Proliposomal and liposomal compositions
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9492387B2 (en) * 2010-10-29 2016-11-15 Western University Of Health Sciences Ternary mixture formulations
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20130045271A1 (en) 2011-08-18 2013-02-21 Monosol Rx, Llc Steroid hormone delivery systems and methods of preparing the same

Also Published As

Publication number Publication date
HK1210409A1 (en) 2016-04-22
CN104780914A (zh) 2015-07-15
PH12014502498A1 (en) 2014-12-22
EP2846781A4 (en) 2016-03-30
CO7240373A2 (es) 2015-04-17
CN108096192A (zh) 2018-06-01
SG10201702240TA (en) 2017-05-30
AU2013259509A1 (en) 2015-01-15
JP6368020B2 (ja) 2018-08-01
EP2846781A2 (en) 2015-03-18
GEP201706754B (en) 2017-10-25
WO2013170012A3 (en) 2015-06-04
CL2014003034A1 (es) 2015-07-03
JP6208842B2 (ja) 2017-10-04
NZ721900A (en) 2018-01-26
EP2846781B1 (en) 2019-10-30
TW201350140A (zh) 2013-12-16
ZA201408996B (en) 2017-08-30
UA115058C2 (uk) 2017-09-11
US8957053B2 (en) 2015-02-17
TW201831169A (zh) 2018-09-01
US20160375036A1 (en) 2016-12-29
JP2018021062A (ja) 2018-02-08
US20140112986A1 (en) 2014-04-24
MX2014013450A (es) 2015-05-11
TN2014000467A1 (en) 2016-03-30
AU2017272249B2 (en) 2019-01-31
US20170065614A1 (en) 2017-03-09
HK1255929A1 (zh) 2019-09-06
TWI664982B (zh) 2019-07-11
JP6055088B2 (ja) 2016-12-27
MA37610A1 (fr) 2016-07-29
JP2017061552A (ja) 2017-03-30
US20180303850A1 (en) 2018-10-25
TWI614035B (zh) 2018-02-11
US20150157572A1 (en) 2015-06-11
AP2014008099A0 (en) 2014-12-31
IN2014DN10383A (es) 2015-08-14
AU2013259509B2 (en) 2017-09-07
CN104780914B (zh) 2018-02-09
EA028809B1 (ru) 2018-01-31
AU2017272249A1 (en) 2017-12-21
IL235464B (en) 2019-09-26
EA201791738A1 (ru) 2018-03-30
ECSP14030572A (es) 2015-11-30
IL235464A0 (en) 2014-12-31
US9623033B2 (en) 2017-04-18
HK1211499A1 (en) 2016-05-27
WO2013170012A2 (en) 2013-11-14
CR20140561A (es) 2015-02-12
US9445995B2 (en) 2016-09-20
CA2872779A1 (en) 2013-11-14
ZA201509340B (en) 2018-05-30
MY175305A (en) 2020-06-18
SG11201407349UA (en) 2014-12-30
NZ702634A (en) 2016-09-30
DOP2015000026A (es) 2015-06-15
AR091006A1 (es) 2014-12-30
KR20150032939A (ko) 2015-03-31
BR112014027942A2 (pt) 2017-06-27
EA201492047A1 (ru) 2015-05-29
JP2015520751A (ja) 2015-07-23
MA37610B1 (fr) 2017-07-31
MX367123B (es) 2019-08-06
US9844557B2 (en) 2017-12-19

Similar Documents

Publication Publication Date Title
PE20150203A1 (es) Formulas de testosterona proliposomal
IN2015DN00544A (es)
TN2015000278A1 (en) Autotaxin inhibitors
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
MX370795B (es) Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida y/o triptófano para influir positivamente en la microbiota intenstinal.
EA201491281A1 (ru) КОМПОЗИЦИЯ В ФОРМЕ СУХОГО ПОРОШКА, СОДЕРЖАЩАЯ КОРТИКОСТЕРОИД И β-АДРЕНЕРГИЧЕСКОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, ДЛЯ ВВЕДЕНИЯ ИНГАЛЯЦИЕЙ
MX2017001432A (es) Peptidos mimeticos de la apoe y mayor potencia para depurar el colesterol en plasma.
MX364220B (es) Metodos de tratamientos de fibrosis.
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
BR112015012081A2 (pt) tratamento de café solúvel
MX2015016410A (es) Esteres de acidos oligo-hidroxicarboxilicos y uso de los mismos.
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
BR112018077350A2 (pt) composições de fosfolipídio
BR112015030594B8 (pt) peça dentária manual para a pulverização de pó
MY160753A (en) Pharmaceutical composition in the form of an oral suspension comprising a flavonoid fraction and xanthan gum
ECSP13013043A (es) Composición oral líquida que comprende sodio divalproex y proceso para preparar la misma
PH12015501179A1 (en) Fixed dose pharmaceutical composition comprising mometasone and azelastine
UA75204U (uk) Спазмолітичний та седативний лікарський засіб у формі м'яких желатинових капсул
PL410457A1 (pl) Kompozycja farmaceutyczna zawierająca kwas dokozaheksaenowy oraz jej zastosowanie
PL406248A1 (pl) Kompozycja farmaceutyczna, zawierająca kwas dokozaheksaenowy, oraz jej zastosowanie
PL405262A1 (pl) Kompozycja farmaceutyczna, zawierająca kwas dokozaheksaenowy, oraz jej zastosowanie
PL411186A1 (pl) Kompozycja farmaceutyczna zawierająca kwas dokozaheksaenowy oraz jej zastosowanie
IN2013CH05770A (es)

Legal Events

Date Code Title Description
FG Grant, registration